# S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

> **NCT00070564** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 3294 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** AC regimen
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00070564
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2003-11
- **Primary completion:** 2015-01
- **Final completion:** 2027-01
- **Target enrollment:** 3294 (ACTUAL)
- **Last updated:** 2025-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070564, "S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT00070564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*